A Phase 3 interventional study of Metformin and Placebo in Covid19 and SARS-CoV Infection, sponsored by University of Minnesota. Completed at 7 sites in United States. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by University of Minnesota · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in COVID-19 by University of Minnesota — none open to participants now, none under way, none of them phase 3. COVID-19 · University of Minnesota.
Among the 21 studies in COVID-19 by University of Minnesota, this one is the 2nd largest by enrollment of the 15 interventional ones that give a count, is one of 5 that started in 2021, is one of 6 in phase 3, and was the 10th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →None of the 21 studies in COVID-19 by University of Minnesota is open now. The open studies under COVID-19, anywhere →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 30 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,323 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 285 across the 15 interventional studies, 108 across the 6 observational. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Minnesota is the lead sponsor of 1,219 studies on the registry; 199 are open to participants now.
Of its 136 completed or terminated interventional studies of FDA-regulated products, 95 (70%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in COVID-19 by University of Minnesota, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly spreading viral infection causing COVID-19 disease. There currently is no definitive preventive or early outpatient treatment therapy for Covid-19. Study study assess 3 existing generic medications: metformin, fluvoxamine, and ivermectin.
Metformin: in-silico, in-vitro, ex-vivo tissue assays suggest that metformin inhibits viral replication of SARS-CoV-2 virus (Castle et al; Gordon et al; and Schaller et al). Several retrospective cohort analyses have suggested an association between taking metformin prior to SARS-CoV-2 infection and less severe outcomes. Kow, J Med Virol conducted a meta analysis, with an overall odds ratio for mortality of 0.62 (0.43-0.89). Gordon et al found decreased SARS-CoV-2 and increased cell viability with metformin in vitro. (Gordon et al, Nature). While anti-viral activity may be contributing to the observational associations of reduced severity of Covid-19, metformin has a proven history of beneficial immune-modulatory effects, including on CRP, IL-6 and TNF-alpha, neutrophil extracellular traps, and improved T cell immunity. Outpatient metformin use has now been associated with lower IL-6, CRP, and neutrophil-lymphocyte ratio in persons with Covid-19 (Lou et al, Diabetes Care 2020).
Fluvoxamine: appears to have anti-inflammatory effects in SARS-CoV-2 infection. There is evidence that SARS-CoV-2 infection causes ER stress and activates pathways of unfolded protein response. Sigma-1 receptor (S1R) is an ER chaperone protein that regulates cytokine production through interaction with IRE1. Fluvoxamine is a selective serotonin reuptake inhibitor that is a powerful S1R agonist. Fluvoxamine has previously been shown to protect mice from septic shock and reduce the inflammatory response. There is potential for fluvoxamine as an immunomodulatory treatment for SARS-Cov-2. Fluvoxamine in CACO2 cells infected with SARS-Cov-2 had a reduction in production of a subset of cytokines including IL-6, IL-8, CXCL1, and CXCL10.53 A randomized controlled clinical trial of 152 patients showed that patients who received fluvoxamine were less likely to experience clinical deterioration, or serious adverse events due to SARS-Cov-2 when compared to placebo (0% vs. 8%). A follow-up real-world observational cohort had similar findings of 0% (0/65) hospitalization with fluvoxamine vs. 12% (6/48) with observation.
Ivermectin has also shown anti-inflammatory effects that would reduce the harmful cytokine cascade noted in severe Covid-19 disease. A recent trial assessing a multi-therapy including 12mg one-time dose of ivermectin found a 75% reduction in hospitalizations. Another small double-blinded RCT showed significant increased chance of viral clearance after a 5-day course of ivermectin. Another March 2021 RCT reported no effect on diminishing symptoms, but was under-powered for assessing reductions in hospitalization. An RCT with ivermectin must be done in the US, as endemic strongyloidiasis in other countries may confound results.
Statistical Considerations:
An independent data safety monitoring board will assess safety approximately twice per month; and will assess futility and efficacy at least twice throughout the study. If one of the arms reaches pre-specified boundaries for futility or efficacy, the DSMB will recommend closing of that arm(s). The detailed statistical analysis plan will be developed by the blinded statistician and co-investigators and per the protocol will be submitted to the DSMB.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of severe kidney disease i.e.:
Medication Exclusions:
The following medications may not need to be excluded when dose for that individual is considered alongside the low dose of fluvoxamine being used and other medications being used. The PI or site PI may review and decide if the patient should be excluded from the fluvoxamine arms:
Taking warfarin-also known as Coumadin, NSAIDs, and Aspirin (rationale: increased risk of bleeding), phenytoin (rationale: fluvoxamine inhibits its metabolism), clopidogrel (rationale: fluvoxamine inhibits its metabolism from pro-drug to active drug which raises risk of cardiovascular events), and St John's wort (rationale: fluvoxamine + St John's wort are considered because of the risk of serotonin syndrome) Risk C, monitor therapy.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is the randomization group that received active metformin + either fluvoxamine placebo or ivermectin placebo.
Drug: Metformin · Drug: Placebo
This is the randomization group that received metformin placebo + either fluvoxamine placebo or ivermectin placebo.
Drug: Placebo
This is the randomization group that received active ivermectin + metformin placebo.
Drug: Placebo · Drug: Ivermectin
This is the randomization group that received active fluvoxamine + metformin placebo.
Drug: Placebo · Drug: Fluvoxamine
This is the randomization group that received active metformin + active fluvoxamine.
Drug: Metformin · Drug: Fluvoxamine
This is the randomization group that received active metformin + active ivermectin.
Drug: Metformin · Drug: Ivermectin
Metformin; immediate release formation; 500mg on Day 1; 500mg BID on Day 2 through Day 5; 500mg in AM and 1,000mg in PM on Day 6 through Day 14.
Also known as: glucophage
placebo; appearance and size are exact matching to the three study drugs.
An antidepressant, administered 50mg per day on Day 1; then 50mg twice-daily for Day 2 through Day 14
Also known as: Luvox
An anti-parasitic medication administered as 390mcg/kg to 470mcg/kg per day for 3 days
Also known as: Stromectol
Clinical Progression to Severe Covid
Clinical progression, defined as Emergency department visit for any COVID-19 related symptom (including hospitalization or death) or decrease in O2 saturation (\<=93% on room air, or need for supplemental oxygen to maintain an O2 saturation \<=93%)
Time frame: 14 Days
Clinical Progression to Severe Covid
Emergency department visit for any COVID-19 related symptom (including hospitalization or death), active relative to placebo
Time frame: 14 days
Progression
Count of participants with clinical progression to Hospitalization, Death
Time frame: 28 days
Maximum Symptom Severity
Defined by adding the symptom score for each individual symptom on the "Daily Symptom Scale Recommended by FDA For Industry." Each symptom on the scale had an answer option ranging from 0 to 3. They corresponded to 0= no symptom; 1=mild symptom; 2=moderate symptom; 3=severe symptom. The range for the total score is 0 to 42 (14 symptoms x 3). The data presented here are the unadjusted mean (SD) for the total symptom score on Day 14.
Time frame: 14 days
Clinical Deterioration: Hospital and Vent >3days
Progression to Hospitalization or Ventilation by Day 28
Time frame: 28 days
Laboratory Outcome Study
Count of participants with no detectable viral load on Day 10.
Time frame: Day5-Day10
All-cause Study Medicine Discontinuation
Study drug discontinuation (total interrupted - total restarted), per treatment allocation. Per treatment allocation means that these counts are not per randomized comparison.
Time frame: 14 days
Long Covid
Proportion of participants with long-covid syndrome, PASC (post-acute sequelae of SARS-CoV-2 infection)
Time frame: Day 300
| Milestone | Randomization Arm - Metformin Only | Randomization Arm - Placebo | Randomization Arm - Ivermectin Only | Randomization Arm - Fluvoxamine Only | Randomization Arm - Metformin and Fluvoxamine | Randomization Arm - Metformin and Ivermectin |
|---|---|---|---|---|---|---|
| Started | 284 | 295 | 206 | 159 | 175 | 204 |
| Completed | 278 | 291 | 206 | 156 | 173 | 201 |
| Not completed | 6 | 4 | 0 | 3 | 2 | 3 |
Clinical progression, defined as Emergency department visit for any COVID-19 related symptom (including hospitalization or death) or decrease in O2 saturation (\<=93% on room air, or need for supplemental oxygen to maintain an O2 saturation \<=93%)
| Participants | Active Metformin | Metformin Placebo | Active Ivermectin | Ivermectin Placebo | Active Fluvoxamine | Fluvoxamine Placebo |
|---|---|---|---|---|---|---|
| Clinical Progression to Severe Covid | 154 | 179 | 105 | 96 | 79 | 80 |
Emergency department visit for any COVID-19 related symptom (including hospitalization or death), active relative to placebo
| Participants | Active Metformin | Metformin Placebo | Active Ivermectin | Ivermectin Placebo | Active Fluvoxamine | Fluvoxamine Placebo |
|---|---|---|---|---|---|---|
| Clinical Progression to Severe Covid | 27 | 48 | 23 | 16 | 18 | 15 |
Count of participants with clinical progression to Hospitalization, Death
| Participants | Active Metformin | Metformin Placebo | Active Ivermectin | Ivermectin Placebo | Active Fluvoxamine | Fluvoxamine Placebo |
|---|---|---|---|---|---|---|
| Progression | 8 | 19 | 4 | 5 | 6 | 5 |
Defined by adding the symptom score for each individual symptom on the "Daily Symptom Scale Recommended by FDA For Industry." Each symptom on the scale had an answer option ranging from 0 to 3. They corresponded to 0= no symptom; 1=mild symptom; 2=moderate symptom; 3=severe symptom. The range for the total score is 0 to 42 (14 symptoms x 3). The data presented here are the unadjusted mean (SD) for the total symptom score on Day 14.
| total score | Active Metformin | Metformin Placebo | Active Ivermectin | Ivermectin Placebo | Active Fluvoxamine | Fluvoxamine Placebo |
|---|---|---|---|---|---|---|
| Maximum Symptom Severity | 3.48 ± 4.0 | 3.73 ± 4.29 | 3.45 ± 4.12 | 3.85 ± 4.28 | 3.53 ± 4.24 | 3.96 ± 4.46 |
Progression to Hospitalization or Ventilation by Day 28
| Participants | Active Metformin | Metformin Placebo | Active Ivermectin | Ivermectin Placebo | Active Fluvoxamine | Fluvoxamine Placebo |
|---|---|---|---|---|---|---|
| Clinical Deterioration: Hospital and Vent >3days | 7 | 18 | 3 | 5 | 6 | 5 |
Count of participants with no detectable viral load on Day 10.
| Participants | Active Metformin | Metformin Placebo | Active Ivermectin | Ivermectin Placebo | Active Fluvoxamine | Fluvoxamine Placebo |
|---|---|---|---|---|---|---|
| Laboratory Outcome Study | 72 | 112 | 53 | 45 | 44 | 42 |
Study drug discontinuation (total interrupted - total restarted), per treatment allocation. Per treatment allocation means that these counts are not per randomized comparison.
| Participants | Randomization Arm - Metformin Only Group | Randomization Arm - Placebo Group | Randomization Arm - Ivermectin Only Group | Randomization Arm - Fluvoxamine Only Group | Randomization Arm - Metformin and Fluvoxamine Group | Randomization Arm - Metformin and Ivermectin Group |
|---|---|---|---|---|---|---|
| All-cause Study Medicine Discontinuation | 56 | 49 | 25 | 32 | 50 | 29 |
Proportion of participants with long-covid syndrome, PASC (post-acute sequelae of SARS-CoV-2 infection)
| Participants | Active Metformin | Metformin Placebo | Active Ivermectin | Ivermectin Placebo | Active Fluvoxamine | Fluvoxamine Placebo |
|---|---|---|---|---|---|---|
| Long Covid | 35 | 59 | 30 | 29 | 30 | 22 |
Collected over Non-COVID adverse events were recorded through Day 14. Covid-related outcomes were recorded through Day 300.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Randomization Arm - Metformin Only | 0/284 (0%) | 0/284 (0%) | 0/284 (0%) |
| Randomization Arm - Placebo | 0/295 (0%) | 0/295 (0%) | 2/295 (0.7%) |
| Randomization Arm - Ivermectin Only | 0/206 (0%) | 0/206 (0%) | 1/206 (0.5%) |
| Randomization Arm - Fluvoxamine Only | 0/159 (0%) | 0/159 (0%) | 0/159 (0%) |
| Randomization Arm - Metformin and Fluvoxamine | 0/175 (0%) | 0/175 (0%) | 0/175 (0%) |
| Randomization Arm - Metformin and Ivermectin | 1/204 (0.5%) | 0/204 (0%) | 0/204 (0%) |
| Event | Randomization Arm - Metformin Only | Randomization Arm - Placebo | Randomization Arm - Ivermectin Only | Randomization Arm - Fluvoxamine Only | Randomization Arm - Metformin and Fluvoxamine | Randomization Arm - Metformin and Ivermectin |
|---|---|---|---|---|---|---|
| neuropathyNervous system disorders | 0/284 | 0/295 | 1/206 | 0/159 | 0/175 | 0/204 |
| dizzinessGeneral disorders | 0/284 | 1/295 | 0/206 | 0/159 | 0/175 | 0/204 |
| weakness in leg/armsMusculoskeletal and connective tissue disorders | 0/284 | 1/295 | 0/206 | 0/159 | 0/175 | 0/204 |
| Age, Continuous(years) | Randomization Arm - Metformin Only | Randomization Arm - Placebo | Randomization Arm - Ivermectin Only | Randomization Arm - Fluvoxamine Only | Randomization Arm - Metformin and Fluvoxamine | Randomization Arm - Metformin and Ivermectin | Total |
|---|---|---|---|---|---|---|---|
| Mean | 46 (36 to 56) | 42 (36 to 54) | 48 (39 to 57) | 46 (38 to 53) | 46 (38 to 53) | 46 (39 to 53) | 46 (37 to 55) |
| Sex: Female, Male(Participants) | Randomization Arm - Metformin Only | Randomization Arm - Placebo | Randomization Arm - Ivermectin Only | Randomization Arm - Fluvoxamine Only | Randomization Arm - Metformin and Fluvoxamine | Randomization Arm - Metformin and Ivermectin | Total |
|---|---|---|---|---|---|---|---|
| Female | 168 | 187 | 108 | 87 | 83 | 108 | 741 |
| Male | 116 | 108 | 98 | 72 | 92 | 96 | 582 |
| Race (NIH/OMB)(Participants) | Randomization Arm - Metformin Only | Randomization Arm - Placebo | Randomization Arm - Ivermectin Only | Randomization Arm - Fluvoxamine Only | Randomization Arm - Metformin and Fluvoxamine | Randomization Arm - Metformin and Ivermectin | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 4 | 4 | 4 | 4 | 1 | 1 | 18 |
| Asian | 7 | 9 | 6 | 5 | 4 | 7 | 38 |
| Native Hawaiian or Other Pacific Islander | 1 | 2 | 0 | 0 | 1 | 1 | 5 |
| Black or African American | 20 | 15 | 12 | 13 | 14 | 13 | 87 |
| White | 213 | 238 | 151 | 125 | 141 | 154 | 1022 |
| More than one race | 10 | 4 | 5 | 4 | 2 | 5 | 30 |
| Unknown or Not Reported | 29 | 23 | 28 | 8 | 12 | 23 | 123 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Jan 2021 to primary completion in Dec 2022, 23 months.
Results were first posted in Jul 2023, 6 months after primary completion.
Of 285 non-industry phase 3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 23 months is above that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Metformin · Fluvoxamine · Ivermectin